These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 30452687)

  • 61. Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance).
    Urbanic JJ; Wang X; Bogart JA; Stinchcombe TE; Hodgson L; Schild SE; Bazhenova L; Hahn O; Salgia R; Vokes EE
    Int J Radiat Oncol Biol Phys; 2018 May; 101(1):177-185. PubMed ID: 29487024
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Nivolumab in never-smokers with advanced squamous non-small cell lung cancer: Results from the Italian cohort of an expanded access program.
    Garassino MC; Crinò L; Catino A; Ardizzoni A; Cortesi E; Cappuzzo F; Bordi P; Calabrò L; Barbieri F; Santo A; Altavilla G; Ambrosio F; Mini E; Vasile E; Morgillo F; Scoppola A; Bengala C; Follador A; Tedde N; Giannarelli D; Lo Russo G; Vitiello F
    Tumour Biol; 2018 Nov; 40(11):1010428318815047. PubMed ID: 30486741
    [TBL] [Abstract][Full Text] [Related]  

  • 63. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial.
    Paz-Ares L; Ciuleanu TE; Cobo M; Schenker M; Zurawski B; Menezes J; Richardet E; Bennouna J; Felip E; Juan-Vidal O; Alexandru A; Sakai H; Lingua A; Salman P; Souquet PJ; De Marchi P; Martin C; Pérol M; Scherpereel A; Lu S; John T; Carbone DP; Meadows-Shropshire S; Agrawal S; Oukessou A; Yan J; Reck M
    Lancet Oncol; 2021 Feb; 22(2):198-211. PubMed ID: 33476593
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nivolumab treatment beyond progressive disease in advanced non-small cell lung cancer.
    Enomoto T; Tamiya A; Matsumoto K; Adachi Y; Azuma K; Inagaki Y; Kouno S; Taniguchi Y; Saijo N; Okishio K; Atagi S
    Clin Transl Oncol; 2021 Mar; 23(3):582-590. PubMed ID: 32661824
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
    Gettinger S; Hellmann MD; Chow LQM; Borghaei H; Antonia S; Brahmer JR; Goldman JW; Gerber DE; Juergens RA; Shepherd FA; Laurie SA; Young TC; Li X; Geese WJ; Rizvi N
    J Thorac Oncol; 2018 Sep; 13(9):1363-1372. PubMed ID: 29802888
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.
    Nieder C; De Ruysscher D; Gaspar LE; Guckenberger M; Mehta MP; Cheung P; Sahgal A
    Strahlenther Onkol; 2017 Jul; 193(7):515-524. PubMed ID: 28424839
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab.
    Bouhlel L; Doyen J; Chamorey E; Poudenx M; Ilie M; Gal J; Guigay J; Benzaquen J; Marquette CH; Berthet JP; Mouroux J; Schiappa R; Padovani B; Hofman P; Otto J
    Bull Cancer; 2020 Sep; 107(9):946-958. PubMed ID: 32646604
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IIIA or IIIB non-small-cell lung cancer.
    Hirose T; Mizutani Y; Ohmori T; Ishida H; Hosaka T; Ando K; Shirai T; Okuda K; Ohnishi T; Horichi N; Kubota H; Adachi M
    Cancer Chemother Pharmacol; 2006 Sep; 58(3):361-7. PubMed ID: 16331494
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A feasibility study of continuous etoposide infusion combined with thoracic radiation for non-small cell lung cancer.
    Oshita F; Kato Y; Yamada K; Nomura I; Sugiyama M; Yamashita K; Kitamura T; Noda K
    Oncol Rep; 1999; 6(2):263-8. PubMed ID: 10022987
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Once-weekly, high-dose stereotactic body radiotherapy for lung cancer: 6-year analysis of 60 early-stage, 42 locally advanced, and 7 metastatic lung cancers.
    Salazar OM; Sandhu TS; Lattin PB; Chang JH; Lee CK; Groshko GA; Lattin CJ
    Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):707-15. PubMed ID: 18455322
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
    Spigel DR; Reynolds C; Waterhouse D; Garon EB; Chandler J; Babu S; Thurmes P; Spira A; Jotte R; Zhu J; Lin WH; Blumenschein G
    J Thorac Oncol; 2018 May; 13(5):682-688. PubMed ID: 29518553
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
    Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
    Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
    Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Duration of nivolumab for pretreated, advanced non-small-cell lung cancer.
    Geier M; Descourt R; Corre R; Léveiller G; Lamy R; Goarant É; Bizec JL; Bernier C; Quéré G; Amrane K; Gaye E; Lucia F; Burte E; Chouaid C; Robinet G
    Cancer Med; 2020 Oct; 9(19):6923-6932. PubMed ID: 32412157
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
    Foster CC; Fleming GF; Karrison TG; Liao CY; Desai AV; Moroney JW; Ratain MJ; Nanda R; Polite BN; Hahn OM; O'Donnell PH; Vokes EE; Kindler HL; Hseu R; Janisch LA; Dai J; Hoffman MD; Weichselbaum RR; Pitroda SP; Chmura SJ; Luke JJ
    Clin Cancer Res; 2021 Oct; 27(20):5510-5518. PubMed ID: 34168049
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Clinical investigation of weekly Carboplatin and Paclitaxel with concurrent radiation therapy for locally advanced non-small cell lung cancer].
    Mito A; Yamasaki M; Matsuura K; Kajihara T; Nitta T; Awaya H; Arita K; Kashiwado K; Ohashi N
    Gan To Kagaku Ryoho; 2009 Oct; 36(10):1653-6. PubMed ID: 19838022
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer.
    Reuss JE; Anagnostou V; Cottrell TR; Smith KN; Verde F; Zahurak M; Lanis M; Murray JC; Chan HY; McCarthy C; Wang D; White JR; Yang S; Battafarano R; Broderick S; Bush E; Brock M; Ha J; Jones D; Merghoub T; Taube J; Velculescu VE; Rosner G; Illei P; Pardoll DM; Topalian S; Naidoo J; Levy B; Hellmann M; Brahmer JR; Chaft JE; Forde PM
    J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929052
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
    Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pneumonitis in Irradiated Lungs After Nivolumab: A Brief Communication and Review of the Literature.
    Manapov F; Roengvoraphoj O; Dantes M; Marschner S; Li M; Eze C
    J Immunother; 2018; 41(2):96-99. PubMed ID: 29200082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.